Clinical trials: Secondary Hyperparathyroidism
Kidney Disease, Secondary Hyperparathyroidism
START: Sensipar Treatment Algorithm to Reach K/DOQI Targets in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism
The purpose of this research is to study the effects and safety of Sensipar approved by the Food and Drug Administration (FDA) in patients with kidney failure who are being treated with dialysis and have uncontrolled secondary…
- Conditions
- Kidney Disease, Secondary Hyperparathyroidism, Chronic Kidney Disease
- Trial name
- NCT00132431
- Testing
- Sensipar
- Volunteers
- 300 people
- Sponsor
- Amgen
Osteoporosis, Secondary Hyperparathyroidism
Calcium and Vitamin D Malnutrition in Elderly Women
This study is designed to test whether calcium supplementation alone or calcium plus vitamin D reduces the incidence of fractures, reduces high parathyroid secretory activity, and halts bone loss in a population-based sample of…
- Trial name
- NCT00352170
- Testing
- calcium supplementation, calcium and vitamin D3 supplementation
- Volunteers
- 1,180 people, healthy volunteers welcome
- Sponsor
- Creighton University
Secondary Hyperparathyroidism
IOPTH Usefulness for Predicting Successful Surgery in Secondary Hyperparathyroidism
Secondary hyperparathyroidism (SHPT) is a multisystemic syndrome that affects calcium and bone homeostasis in patients with chronic kidney disease (CKD).
- Trial name
- NCT04484116
- Testing
- Intraoperative Paratohormone
- Where
- Mexico
- Volunteers
- 30 people
- Sponsor
- Hospital General Ajusco Medio
Renal Osteodystrophy
Low Magnitude Mechanical Stimuli Effects on Bone Structure in ESRD
The proposed 6 month pilot and feasibility randomized trial will evaluate LMMS as an anabolic stimulus to bone in 30 adults on maintenance hemodialysis.
- Trial name
- NCT00364234
- Testing
- Low magnitude mechanical stimuli
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Secondary Hyperparathyroidism, Hemodialysis
Paricalcitol Compared to Maxacalcitol in Chronic Kidney Disease Patients With Secondary Hyperparathyroidism
This study is a exploratory comparison of the efficacy and safety of paricalcitol injection with maxacalcitol injection in chronic kidney disease participants receiving hemodialysis with secondary hyperparathyroidism.
- Trial name
- NCT00990704
- Testing
- paricalcitol, maxacalcitol
- Where
- 14 sites in Japan
- Volunteers
- 47 people
- Sponsor
- Abbott
Secondary Hyperparathyroidism, Hemodialysis
Comparison of Efficacy and Safety of Paricalcitol Injection With Maxacalcitol Injection in Adult Japanese Chronic Kidney Disease Subjects Receiving Hemodialysis With Secondary Hyperparathyroidism
This study is a comparison of the efficacy and safety of paricalcitol injection with maxacalcitol injection in adult Japanese chronic kidney disease patients receiving hemodialysis with secondary hyperparathyroidism.
- Trial name
- NCT01341782
- Testing
- paricalcitol, maxacalcitol
- Where
- 45 sites in Japan
- Volunteers
- 255 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Chronic Kidney Diseases, Hypertension
Integrated Diagnosis and Treatment of CKD on Outcomes
Objective: To establish a study cohort and follow up of patients with CKD in our hospital, and evaluate the status of integrated CKD diagnosis and treatment according to guidelines in the real world, as well as the clinical…
- Conditions
- Chronic Kidney Diseases, Hypertension, Hyperglycemia, Hyperlipidemias
- Trial name
- NCT05242055
- Testing
- Integrated diagnosis and treatment for CKD
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Capital Medical University
Secondary Hyperparathyroidism, Dialysis
Efficacy and Safety of 6 Months Treatment With Paricalcitol Injection or Oral in Patients With Secondary Hyperparathyroidism on Dialysis
Prospective, non-randomized, multi-center study to assess the efficacy and safety of paricalcitol injection or oral administered over 6 months to patients with secondary hyperparathyroidism on dialysis.
- Trial name
- NCT00537979
- Testing
- Paricalcitol injection, Paricalcitol capsules
- Where
- 12 sites in Mexico
- Volunteers
- 147 people
- Sponsor
- Abbott
Hyperparathyroidism, Secondary, Hyperparathyroidism, Primary
Study on the Use of Cinacalcet in Phosphocalcic Context.
Currently, the indications used for MA (Marketing Authorization) Cinacalcet in France are hyperparathyroidism (hyperPTH) in adults, whether primary (for patients in whom parathyroidectomy is theoretically indicated but in whom it…
- Trial name
- CALCI-CINA (NCT04126954)
- Testing
- Serum PTH concentrations results
- Where
- 10 sites in France
- Volunteers
- 25 people
- Sponsor
- Hospices Civils de Lyon
Hyperparathyroidism; Secondary, Renal
Efficacy and Safety of Cinacalcet in Ca, P and iPTH Levels in Patients With Mild, Moderate and Severe SHPT
1. To evaluate achievement ratio of iPTH,Calcium and phosphorus after taking Cinacalcet HCL in hemodialysis subjects with mild, moderate and severe SHPT; 2.
- Trial name
- ACTIVE (NCT03123406)
- Testing
- Cinacalcet HCl
- Where
- China
- Volunteers
- 750 people
- Sponsor
- Kyowa Kirin China Pharmaceutical Co., Ltd.
Hyperphosphatemia
The Effect of Oral Niacinamide on Serum Phosphorus Levels in Hemodialysis Patients
Elevated phosphorus levels are a common problem in dialysis patients. However, it is associated with an increase in death and hospitalizations.
- Trial name
- NCT00316472
- Testing
- Niacinamide
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Washington University School of Medicine
Secondary Hyperparathyroidism;Parathyroidectomy
Total Parathyroidectomy With Autotransplantation Versus Total Parathyroidectomy Alone for Secondary Hyperparathyroidism
Total parathyroidectomy with autotransplantation (TPTX+AT) and Total parathyr- oidectomy alone (TPTX) are the common surgical procedures.The purpose of the study was to compare the long-term benefits of surgery between the two…
- Trial name
- NCT04922892
- Testing
- Parathyroidectomy
- Where
- China
- Volunteers
- 200 people
- Sponsor
- The Second Hospital of Nanjing Medical University
Chronic Kidney Failure, Secondary Hyperparathyroidism
Paricalcitol Oral Therapy in Predialysis CKD Patients. The Greek Experience
The purpose of this study is to obtain data on the use of Zemplar (paricalcitol) capsules in real-life clinical practice in predialysis patients with chronic kidney disease (CKD) and secondary hyperparathyroidism.
- Trial name
- PROTECT (NCT01083186)
- Where
- 24 sites in Greece
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- AbbVie (prior sponsor, Abbott)
End-Stage Renal Disease, Secondary Hyperparathyroidism
A Study to Evaluate the Safety of Paricalcitol Capsules in Pediatric Subjects Ages 10 to 16 With Stage 5 Chronic Kidney Disease Receiving Peritoneal Dialysis or Hemodialysis
The objective is to evaluate the safety of paricalcitol capsules in pediatric subjects, ages 10 to 16 years old, with Stage 5 chronic kidney disease (kidney failure) receiving peritoneal dialysis or hemodialysis and being treated…
- Trial name
- NCT01382212
- Testing
- paricalcitol
- Volunteers
- 13 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Secondary Hyperparathyroidism
Bone Biopsy Study For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease
The purpose of this study is to evaluate the effects of cinacalcet on markers of bone turnover in patients with kidney disease who are receiving dialysis.
- Trial name
- BONAFIDE (NCT00261950)
- Testing
- Sensipar (Cinacalcet HCl)
- Where
- 55 sites in United States, Belgium and 10 more
- Volunteers
- 110 people
- Sponsor
- Amgen
Roux-en-Y Gastric Bypass, Hyperparathyroidism, Secondary
Investigation of the Optimal Calcium Supplement Following Roux-en-Y Gastric Bypass
This study investigates whether calcium citrate or calcium carbonate are the optimal supplement to treat secondary hyperparathyroidism following Roux-en-Y gastric bypass operation.
- Trial name
- NCT02830789
- Testing
- Calcium Carbonate, Calcium Citrate, Roux-en-Y gastric bypass
- Where
- Denmark
- Volunteers
- 38 people
- Sponsor
- University of Aarhus
Kidney Failure, Chronic
Observational Study to Evaluate the Time to Achieving the Maintenance Dose of Zemplar® (Paricalcitol Injection) in the Treatment of Patients Suffering From End-stage Renal Disease and Severe Over-reactivity of the Parathyroid Glands
This observational study will evaluate the clinical benefit of Zemplar (paricalcitol injection) in daily routine practice in end-stage renal disease patients with severe over-reactivity of parathyroid glands.
- Trial name
- NCT01273597
- Where
- 11 sites in Hungary
- Volunteers
- 60 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Postmenopausal Osteoporosis, Postmenopause
Frequency of Hyperparathyroidism in Postmenopausal Osteoporosis and Its Treatment
Recently, an increase in the prevalence of hyperparathyroidism and hypovitaminosis D in postmenopause women has been occurring in Mexico and the world.
- Conditions
- Postmenopausal Osteoporosis, Postmenopause, Hyperparathyroidism, Secondary, Hypovitaminosis D
- Trial name
- NCT05347082
- Testing
- Cholecalciferol
- Where
- Mexico
- Volunteers
- 47 people
- Sponsor
- Hospital Regional 1o de Octubre
Hyperparathyroidism, Chronic Kidney Disease
Sevelamer and Secondary Hyperparathyroidism in Chronic Kidney Disease
The hypothesis underlying this study is that phosphate interferes with PTH-mediated calcium reabsorption in the distal nephron and thereby necessitates supranormal [PTH]to maintain normocalcemia in chronic kidney disease.
- Trial name
- NCT01191762
- Testing
- sevelamer carbonate
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Kenneth R. Phelps, M.D.
Chronic Kidney Disease 5D, Secondary Hyperparathyroidism Due to Renal Causes
A Study on Prevention Strategies for CKD-SHPT and Related Complications Based on General Vitamin D Supplementation
1. Study content: This is a multicentre, double-blind, randomised controlled study to determine the optimal dose and duration of treatment for the correction of vitamin D insufficiency or deficiency in patients with CKD5d; to…
- Conditions
- Chronic Kidney Disease 5D, Secondary Hyperparathyroidism Due to Renal Causes, Vitamin D Deficiency
- Trial name
- NCT05549154
- Testing
- High-dose vitamin D2 softgels, low-dose vitamin D2 softgels
- Where
- China
- Volunteers
- 372 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University